If you are researching TRT in the UK, one of the first decisions is whether to pursue Testosterone Replacement Therapy through the NHS or through a private TRT clinic.
Both routes can provide legitimate medical treatment, but the patient experience can differ considerably. Waiting times, qualifying thresholds, blood testing, available testosterone preparations, fertility management, prescribing flexibility and ongoing monitoring may all differ between NHS and private care.
For many men, the question is therefore not simply whether TRT is available in the UK. It is how testosterone deficiency is assessed, which treatment options are realistically available and how much individualisation is possible once treatment begins.
This guide explains the NHS and private TRT pathways, commonly used testosterone medications including Testogel, Sustanon and Nebido, testosterone thresholds, fertility considerations and the differences patients may encounter during long-term treatment.
Testosterone is a prescription medicine in the UK. Treatment should therefore follow appropriate clinical assessment rather than simply purchasing testosterone independently because symptoms appear compatible with low testosterone.
The NHS pathway normally begins through primary care. A GP may arrange morning testosterone testing and investigate other potential explanations for symptoms before considering specialist referral.
Private TRT clinics usually provide a more direct pathway. Blood testing, symptoms, medical history, hormone markers and treatment suitability can often be assessed within the same specialist pathway.
In either setting, symptoms matter. Fatigue, reduced libido, erectile difficulties, low mood, reduced motivation and changes in body composition are not specific to testosterone deficiency and should not be used alone to diagnose hypogonadism.
One of the most important differences between NHS and private TRT pathways is how testosterone results are interpreted alongside symptoms.
In real-world NHS practice, men with repeat Total Testosterone results above approximately 8 nmol/L frequently struggle to progress towards TRT, particularly where there is no clearly established pathological cause.
Exact referral and treatment criteria vary between NHS trusts, specialists and local pathways, so this should not be interpreted as a universal national cutoff.
Private UK TRT clinics may consider symptomatic men with Total Testosterone considerably above the levels typically treated through NHS pathways.
A figure around 15 nmol/L is commonly encountered as an upper boundary for further clinical consideration rather than an automatic threshold for treatment.
Free Testosterone can become particularly relevant where Total Testosterone does not appear severely reduced but symptoms remain convincing.
Many private assessments pay particular attention to Free Testosterone below approximately 0.30 nmol/L, while some clinical pathways may exercise discretion at somewhat higher values, including around 0.35 nmol/L, depending on symptoms and the wider hormonal picture.
These figures describe how UK pathways may operate in practice. They are not standalone diagnostic rules. Testosterone results should be considered alongside symptoms, repeat testing, SHBG, Free Testosterone and the wider clinical context.
NHS care can provide appropriate testosterone replacement for men with confirmed hypogonadism, but the pathway is commonly more conservative and may take considerably longer than private assessment.
Symptoms are discussed and alternative explanations may be considered.
Testosterone is normally assessed using appropriately timed blood testing.
An abnormal or borderline result may need confirmation before a diagnosis is considered.
Men meeting local criteria may be referred to endocrinology or another appropriate specialist service.
Testosterone replacement may be offered where hypogonadism has been appropriately established.
Testosterone response, blood markers and treatment safety require follow-up after treatment begins.
The most common difficulty occurs when symptoms and laboratory results do not fit neatly into a clearly severe biochemical deficiency.
A man may experience reduced libido, fatigue, poorer erections, reduced motivation and other compatible symptoms while his Total Testosterone remains above the level at which his local NHS service is prepared to investigate or treat further.
SHBG can complicate this further because Total Testosterone does not always reflect the amount of testosterone available to tissues. This is one reason Free Testosterone can provide useful additional context.
NHS care also varies geographically. Referral criteria, preferred testosterone preparations and shared-care arrangements can differ between local formularies and specialist services.
Local NHS formularies differ, but testosterone gels and injectable preparations such as Sustanon and Nebido are commonly encountered in male hypogonadism treatment.
Testosterone gel is commonly used within NHS testosterone replacement pathways. Depending on local prescribing policy, products may include Testogel, Testavan or Tostran.
Gel is applied to the skin every day and avoids injections, although individual absorption can vary and accidental transfer to another person needs to be considered.
Sustanon is a mixture of four testosterone esters and is an established injectable option in UK medicine.
NHS administration schedules may use relatively widely spaced intramuscular injections. Private TRT clinics may instead use smaller amounts more frequently where clinically appropriate.
Nebido contains testosterone undecanoate and is designed to provide prolonged testosterone exposure from a deep intramuscular injection.
Its much longer duration allows considerably longer intervals between injections than shorter-acting testosterone preparations.
Testosterone enanthate is another injectable testosterone preparation available within UK medicine and appears on some NHS formularies.
It is also widely discussed in private TRT because its pharmacokinetic profile allows dosing frequency to be tailored to the individual treatment plan.
The testosterone preparation offered through the NHS can depend on local formulary decisions, specialist preference, clinical response and practical considerations. A medication available in one area may not necessarily be the preferred first-line option in another.
Sustanon and Nebido both deliver testosterone by intramuscular injection, but they have very different pharmacokinetic profiles and administration schedules.
Private TRT is often chosen by men who want faster assessment, broader hormone testing and more flexibility when discussing how testosterone replacement is delivered.
This can be particularly relevant for men whose testosterone is above the level generally progressed through NHS pathways but who continue to experience significant symptoms and have other biochemical evidence that may support further investigation.
Private assessment is also more likely to explore Total Testosterone, Free Testosterone and SHBG together rather than interpreting Total Testosterone completely in isolation.
Depending on the clinic, treatment discussions may include testosterone cypionate, enanthate, Sustanon, gels, compounded creams and fertility-related treatment strategies.
Fertility should be considered before testosterone treatment begins, particularly in younger men who may want biological children in the future.
Exogenous testosterone suppresses the hypothalamic-pituitary- gonadal axis and can reduce intratesticular testosterone and sperm production. Fertility goals should therefore be discussed before treatment rather than after suppression has occurred.
TRT & Fertility GuidehCG may be used within specialist male reproductive or private hormone medicine, but it is not normally part of a standard NHS testosterone replacement protocol for male hypogonadism.
hCG on TRT ExplainedA man seeking symptom improvement from hypogonadism and a man actively trying to conceive may require different clinical strategies. Testosterone itself can suppress spermatogenesis, which is why future fertility should form part of the initial consultation.
Aromatase inhibitors such as anastrozole, exemestane and letrozole are not routine components of standard NHS testosterone replacement therapy.
These medications reduce oestrogen synthesis by inhibiting aromatase. Although they may sometimes appear within specialist or private hormone care, a higher oestradiol result does not automatically mean pharmacological suppression is required.
Oestradiol performs important physiological functions in men. Excessive suppression may contribute to sexual symptoms, musculoskeletal problems and adverse effects on bone health.
Tamoxifen is also sometimes discussed in men's hormone medicine, particularly around breast symptoms, but it is a SERM rather than an aromatase inhibitor and acts through a different mechanism.
Neither route can be reduced to a single advantage or disadvantage. What matters is whether the pathway provides appropriate diagnosis, treatment and monitoring for the individual patient.
Starting testosterone is only one part of TRT. Appropriate long-term treatment also requires monitoring of response, blood results and potential adverse effects.
Results should be interpreted according to the treatment used and timing of the blood sample.
Testosterone can increase red blood cell production, making full blood count and haematocrit monitoring important.
Age, symptoms, baseline risk and clinical circumstances determine how prostate health should be assessed.
Oestradiol may provide additional context where clinically relevant symptoms or unexpected hormone results occur.
Cardiovascular risk factors and blood pressure remain part of sensible long-term health monitoring.
Laboratory numbers should be considered alongside how the patient is actually responding to treatment.
NHS treatment has an obvious financial advantage because most of the clinical pathway is funded through the health service.
Private TRT requires the patient to pay for some combination of consultations, blood testing, prescriptions, medication and ongoing clinical support.
The important comparison is therefore not simply NHS treatment versus a monthly private price. Private clinic models differ, and some include follow-up services within a subscription while others charge separately for medication, blood tests or consultations.
Men considering private treatment should therefore calculate the realistic annual cost rather than judging a clinic from the lowest advertised monthly figure.
Private treatment is not automatically better simply because it is private, and NHS treatment is not automatically inadequate simply because its pathways are more conservative.
What matters is whether testosterone deficiency has been properly assessed, other causes of symptoms have been considered, the prescribed treatment is appropriate and ongoing monitoring is adequate.
A responsible private clinic should not prescribe testosterone simply because somebody is willing to pay for it. Equally, a symptomatic patient deserves a meaningful assessment rather than having the clinical conversation end with a single laboratory number.
TRT in the UK can be accessed through either NHS or private medical care, but the pathways often look very different in practice.
NHS testosterone treatment provides a low-cost route for men who meet the relevant diagnostic and local referral criteria. Private TRT can provide faster assessment, broader investigation and greater treatment flexibility, particularly for men who sit outside the thresholds commonly progressed through NHS services.
Neither pathway changes the fundamental principle that TRT is a medical treatment. Symptoms, repeat testosterone testing, Free Testosterone, SHBG, fertility goals, medical history and long-term monitoring all matter.
The aim should not simply be to obtain testosterone. It should be to establish whether testosterone deficiency is genuinely present and, where treatment is appropriate, manage it safely over the long term.
Continue exploring diagnosis, bloodwork, treatment options and testosterone medications used in UK TRT.
Common questions about NHS TRT, private testosterone treatment, testosterone thresholds and TRT medications in the UK.
Yes. Testosterone replacement therapy is available through the NHS for appropriately diagnosed testosterone deficiency. Access usually involves symptoms, biochemical testing and, depending on the local pathway, specialist assessment.
NHS pathways vary, but in real-world practice men with repeat Total Testosterone above approximately 8 nmol/L often find it difficult to progress towards treatment. This is not a universal national cutoff, and clinical circumstances and local referral criteria differ.
Potentially. Private TRT clinics may assess symptomatic men with Total Testosterone considerably above levels normally progressed through NHS pathways. Some clinics may consider men with Total Testosterone up to around 15 nmol/L where the wider clinical picture supports further assessment.
Interpretation depends on the laboratory method and clinical context. Within private UK hormone care, Free Testosterone below approximately 0.30 nmol/L may receive particular attention, while some clinicians may consider somewhat higher values where symptoms and other findings support further investigation.
Testosterone gels are widely used within NHS testosterone replacement pathways. Depending on the local formulary, products may include Testogel, Testavan or Tostran.
Sustanon appears on multiple NHS formularies and can be used as an injectable testosterone preparation. The administration schedule and whether it is preferred locally depend on the relevant NHS service.
Yes, Nebido is used within NHS testosterone replacement pathways. It contains long-acting testosterone undecanoate and allows much longer intervals between injections than shorter-acting preparations.
hCG is not normally part of routine NHS testosterone replacement for male hypogonadism. Fertility treatment and reproductive endocrinology follow different clinical pathways, so men who want to preserve fertility should discuss this before beginning testosterone.
Aromatase inhibitors are not standard routine additions to NHS testosterone replacement therapy. They have other recognised medical uses and may be considered in specialist circumstances, but an elevated oestradiol result alone does not automatically mean an AI is required.
Yes. Testosterone can be prescribed privately by an appropriately qualified clinician following proper medical assessment. Private treatment does not remove the need for diagnosis, prescribing standards or ongoing clinical monitoring.
Not automatically. Private TRT may provide faster access, broader investigation and greater treatment flexibility, while NHS care offers treatment at much lower direct cost. The important issue is whether the patient receives appropriate diagnosis, treatment and long-term monitoring.
There is no single testosterone preparation that is best for every patient. Gels, Sustanon, Nebido, testosterone enanthate and other preparations have different advantages and limitations. Treatment should be selected according to the individual's diagnosis, response, preferences and clinical circumstances.
This guide is provided for general educational purposes and does not replace personalised medical advice, diagnosis or treatment. NHS referral criteria, formularies and prescribing pathways vary between regions and may change over time. Testosterone, hCG and other hormone-modifying medicines should only be used under appropriate clinical supervision.
